Aug 20 (Reuters) - Canada's Valeant Pharmaceuticals (NYSE:VRX)
International Inc VRX.TO is nearing a deal to pay $1 billion
for Sprout Pharmaceuticals, the company that just won approval
to sell the first drug that aims to boost a woman's libido, the
Wall Street Journal reported.
Valeant would pay all cash, one $500 million installment
upfront and one next year, for Sprout Pharmaceuticals and its
pink libido pills that will be sold under the brand name Addyi,
the Journal reported, citing a person familiar with the matter.
(http://on.wsj.com/1K7qXds)
Reuters could not immediately reach Valeant or Sprout for
comment outside regular business hours.